Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk (LAM2006IR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00860639|
Recruitment Status : Completed
First Posted : March 12, 2009
Last Update Posted : January 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia||Drug: gemtuzumab ozogamycin||Phase 3|
Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course. The induction course include: Daunorubicin for 3 days (60mg/m²) associated with cytarabine (200mg/m²) for 7 days. The MYLOTARG ® will be administered according to the randomization arm on the 4th day of treatment by slow intravenous infusion of 2 hours at a dose of 6 mg/m2. Early bone marrow assessment will be performed at D15. In case of blast excess (>5%) , a second course of induction will be administered.
The consolidation treatment depends on age, molecular prognostic factors, and donor availability:
- Patients with good molecular prognosis profile [ NPM1 + / FLT3 ITD - or CEBPa mutated ] will be consolidated by two courses of intensive chemotherapy comprising Mitoxanthrone and intermediate dose of Cytarabine with or without MYLOTARG ® according to the initial randomization during the first course.
- Patients younger than 51 years, eligible for standard allogeneic transplantation with sibling or full matched unrelated donor will receive a standard bone marrow transplantation which not begin before 90 days after the induction.
- Patients with no donor or older than 50 years, or with a donor being identified, will receive two courses of intensive consolidation comprising Mitoxantrone and intermediate-dose of Cytarabine with or without Mylotarg ® 6 mg / m² during the first consolidation according to the randomisation arm.
- Patients aged 51 to 60 years with an HLA identical donor (sibling or unrelated), will receive a non-myeloablative haematopoietic stem cells transplant (HSCT) after the second course of consolidation.
- For other patients, an autologous hematopoietic stem cells transplant (HSCT) will be performed after the 2nd course of consolidation. Collection of peripheral blood stem cells (PBSCs) will be performed after the first consolidation course and a second collection may be considered after the second consolidation course in case of inadequate collection.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||327 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk|
|Study Start Date :||October 2007|
|Primary Completion Date :||September 26, 2016|
|Study Completion Date :||September 26, 2016|
Active Comparator: gemtuzumab ozogamycin
Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
Drug: gemtuzumab ozogamycin
gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
Other Name: gemtuzumab ozogamycin (MYLOTARG ®)
|No Intervention: without Mylotarg|
- event free survival (EFS)after 3 years for patients not eligible for standard allogenic transplantation [ Time Frame: 3 years ]
- Complete Remission Rate (CR) Overall Survival at 3 years Relapse rate at 3 years Toxicity and tolerability of each treatment arm Evaluation of Minimal residual disease by WT1 and NPM1 study at different phases of treatment. [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00860639
|CH Pays d'Aix|
|Centre Hospitalier de la Côte Basque|
|CHU Hôpital Minjoz|
|CHU Hôtel Dieu|
|CH Louis Pasteur|
|CHU du Bocage|
|Institut Paoli Calmette|
|CH Metz Thionvile|
|CHU Hôtel Dieu|
|CH La Source|
|Hopital Cochin (AP-HP)|
|CHU du Haut Lévèque|
|CHU Jean Bernard - La Milétrie|
|CHU Robert Debré|
|Institut de Cancérologie de la Loire|
|Saint Etienne, France|
|Vandoeuvre Les Nancy, France|
|Principal Investigator:||Jacques Delaunay, MD||Nantes University Hospital|